Currently, while taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 2.71. ABR value is precisely based on brokerage recommendations, where out of 7 brokerage recommendations 1 rate Clovis Oncology, Inc. stock a Strong Buy, 0 rate the stocks of the company a Buy, 6 rate Hold, 0 rate Sell and 0 recommend a Strong Sell.
Clovis Oncology, Inc., belongs to Healthcare sector and Biotechnology industry. The company’s Market capitalization is $428.98MB with the total Outstanding Shares of 53.69M. On 25-02-2020 (Tuesday), CLVS‘s stock construct a change of -19.46% in a total of its share price and finished its trading at 7.99.
CLVS Stocks -20.61% Far from 50 Day Moving Average
After a stumble in the market that brought CLVS to its low price for the period of the last 52 weeks, Clovis Oncology, Inc. was unable to take a rebound, for now settling with 172.70% of loss for the given period.
Having a look at past record, we’re going to look at various forwards or backwards shifting developments regarding CLVS. The firm’s shares fell -13.71% in the past five business days and declined -10.48% in the past thirty business days. In the previous quarter, the stock rose 2.96% at some point. The output of the stock increased 34.29% within the six-month closing period, while general annual output decreased -68.63%. The company’s performance is now negative at -23.36% from the beginning of the calendar year.
Earnings per Share Details of Clovis Oncology, Inc.
Lets a quick look at CLVS’s past reported and future predictions of growth using the EPS Growth. EPS growth is a percentage change in standardized earnings per share over the trailing-twelve-month period to the current year-end.
The company posted a value of $-80.50% as earning-per-share over the last full year, while a chance, will post $32.70% for the coming year. In-depth, if we analyze for the long-term EPS Growth, the out-come was -19.10% for the past five years and the scenario is totally different as the current prediction is 61.20% for the next five year.
P/S, P/E, P/C and P/B/ SMA50, SMA 200:
The price-to-sales is a valuation ratio that relates a company’s stock price to its revenues. The price-to-sales ratio is a symbol of the value placed on each dollar of a company’s sales or taxes. As of now, CLVS has a P/S, P/E and P/B values of 3.20, N/A and N/A respectively. P/E and P/B ratios both are used on a regular basis by the investor to measure the value of the company and to get the right amount of the share.
Its P/Cash valued at 1.21. The price-to-cash-flow ratio is a stock valuation indicator that measures the value of a stock’s price to its cash flow per share. Investors focus on the profitability proportions of the company that how the company performs at profitability side. Return on equity ratio or ROE is a significant indicator for prospective investors as they would like to see just how effectively a business is using their cash to produce net earnings.
Watching some historical volatility numbers on shares of Clovis Oncology, Inc. (CLVS) we can see that the 30 days volatility is presently 9.37%. The 7 days volatility is 14.33%. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.
The company has a beta of Clovis Oncology, Inc. 1.00 indicates that its price is correlated with the market. Less than 1.00 shows less volatility than the market. Beta greater than 1.00 indicates that the security’s price is theoretically more volatile than the market.
As a return on equity, Clovis Oncology, Inc. (NASDAQ: CLVS) produces N/A. Because it would be easy and highly flexible, ROI measurement is among the most popular investment ratios. Executives could use it to evaluate the levels of performance on acquisitions of capital equipment whereas investors can determine that how the stock investment is better. The ROI entry for CLVS’s scenario is at -50.10%. Another main metric of a profitability ratio is the return on assets ratio or ROA that analyses how effectively a business can handle its assets to generate earnings over duration of time. Clovis Oncology, Inc. (CLVS) generated -52.50% ROA for the trading twelve-month.
What do you mean by simple moving average (SMA)?
Based on a recent bid, its distance from 20 days simple moving average is -15.51%, and it has a distance of -15.06% from the 200 days simple moving average.
The payout ratio shows the proportion of earnings paid out as dividends to shareholders, typically expressed as a percentage of the company’s earnings. The payout ratio can also be expressed as dividends paid out as a proportion of cash flow. The payout ratio is also known as the dividend payout ratio. The Company’s payout ratio was N/A and Price to free cash flow remained $N/A.